Propanc Biopharma (PPCB) Enterprise Value (2015 - 2025)
Propanc Biopharma (PPCB) posted quarterly Enterprise Value of -$602737.0 for Q3 2025, down 6403.42% year-over-year from $9562.1 in Q3 2024, and down 4886.24% quarter-over-quarter from -$12088.0 in Q2 2025.
Propanc Biopharma (PPCB) Enterprise Value (2015 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Enterprise Value for 11 consecutive years, with -$602737.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Enterprise Value fell 6403.42% year-over-year to -$602737.0; the TTM figure through Sep 2025 stood at -$602737.0 (down 6403.42% YoY), while the FY2025 annual figure was -$12088.0, up 42.67% from the prior year.
- Enterprise Value slipped to -$602737.0 in Q3 2025 per PPCB's latest filing, from -$12088.0 in the prior quarter.
- Across five years, Enterprise Value topped out at -$2255.0 in Q2 2021 and bottomed at -$602737.0 in Q3 2025.
- Historically, Enterprise Value has averaged -$60134.6 across 5 years, with a median of -$17014.5 in 2022.
- Annual changes were most pronounced in 2024 — Enterprise Value soared 93.33% — and 2025, when it plunged 6403.42%.
- Propanc Biopharma's Enterprise Value stood at -$73616.0 in 2021, then surged by 66.75% to -$24476.0 in 2022, then slumped by 192.74% to -$71650.0 in 2023, then surged by 79.58% to -$14633.0 in 2024, then sank by 4019.03% to -$602737.0 in 2025.
- Business Quant data shows PPCB's Enterprise Value at -$602737.0 in Q3 2025, -$12088.0 in Q2 2025, and -$50760.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | -561,237.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -602,737.00 |
| Jun 30, 2025 | -12,088.00 |
| Mar 31, 2025 | -50,760.00 |
| Dec 31, 2024 | -14,633.00 |
| Sep 30, 2024 | -9,268.00 |
| Jun 30, 2024 | -21,085.00 |
| Mar 31, 2024 | -6,222.00 |
| Dec 31, 2023 | -71,650.00 |
| Sep 30, 2023 | -6,625.00 |
| Jun 30, 2023 | -10,047.00 |
| Mar 31, 2023 | -93,241.00 |
| Dec 31, 2022 | -24,476.00 |
| Sep 30, 2022 | -19,396.00 |
| Jun 30, 2022 | -4,067.00 |
| Dec 31, 2021 | -73,616.00 |
| Sep 30, 2021 | -45,817.00 |
| Jun 30, 2021 | -2,255.00 |
| Mar 31, 2021 | -14,439.00 |
| Dec 31, 2020 | -21,243.00 |
| Mar 31, 2020 | -26,957.00 |